Neuroprotection in Acute Ischemic Stroke
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Neuroprotection in Acute Ischemic Stroke is a clinical trial[1].
Key Facts
- Neuroprotection in Acute Ischemic Stroke is in the country of United States[2].
- Neuroprotection in Acute Ischemic Stroke's instance of is recorded as clinical trial[3].
- Neuroprotection in Acute Ischemic Stroke's start time is recorded as +2017-08-02T00:00:00Z[4].
- Neuroprotection in Acute Ischemic Stroke's end time is recorded as +2020-08-02T00:00:00Z[5].
- Neuroprotection in Acute Ischemic Stroke's sponsor is recorded as Stony Brook University[6].
- Neuroprotection in Acute Ischemic Stroke's main subject is recorded as stroke[7].
- Neuroprotection in Acute Ischemic Stroke's main subject is recorded as ischemia[8].
- Neuroprotection in Acute Ischemic Stroke's number of participants is recorded as {'unit': '1', 'amount': '+100'}[9].
- Neuroprotection in Acute Ischemic Stroke's title is recorded as Pilot Study of the Neuroprotective Effects of Hydrogen and Minocycline in Acute Ischemic Stroke[10].
- Neuroprotection in Acute Ischemic Stroke's short name is recorded as H2M[11].
- Neuroprotection in Acute Ischemic Stroke's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[12].
- Neuroprotection in Acute Ischemic Stroke's ClinicalTrials.gov ID is recorded as NCT03320018[13].
- Neuroprotection in Acute Ischemic Stroke's research intervention is recorded as minocycline[14].
- Neuroprotection in Acute Ischemic Stroke's clinical trial phase is recorded as phase II clinical trial[15].
- Neuroprotection in Acute Ischemic Stroke's clinical trial phase is recorded as phase III clinical trial[16].
- Neuroprotection in Acute Ischemic Stroke's research site is recorded as Stony Brook University[17].
- Neuroprotection in Acute Ischemic Stroke's study type is recorded as interventional study[18].